Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

89.50DKK
10:59am EDT
Change (% chg)

kr.-2.10 (-2.29%)
Prev Close
kr.91.60
Open
kr.92.00
Day's High
kr.92.20
Day's Low
kr.88.60
Volume
72,878
Avg. Vol
69,846
52-wk High
kr.127.00
52-wk Low
kr.78.50

Latest Key Developments (Source: Significant Developments)

Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln
Friday, 27 Apr 2018 01:33am EDT 

April 27 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018.NET SALES OF SOLIQUA(®) 100/33 AND LYXUMIA(®)/ADLYXIN(®) OF EUR 14.5 MILLION/USD 17.9 MILLION IN Q1 2018.  Full Article

Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome
Thursday, 26 Apr 2018 12:50am EDT 

April 26 (Reuters) - Zealand Pharma A/S ::ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME.SAYS PIVOTAL PHASE 3 TRIAL IS ON TRACK FOR INITIATION IN Q3 2018.ZEALAND EXPECTS TO INITIATE PIVOTAL PHASE 3 TRIAL IN Q3 2018.SCIENTIFIC ADVICE WITH EUROPEAN MEDICINES AGENCY (EMA) IS ONGOING WITH AN EXPECTED OUTCOME BY MID-2018.  Full Article

Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon
Wednesday, 11 Apr 2018 07:55am EDT 

April 11 (Reuters) - Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu ::ZEALAND AND ROCHE DIABETES CARE ENTER PHASE 3 STUDY COLLABORATION FOR TREATMENT OF CONGENITAL HYPERINSULINISM WITH DASIGLUCAGON.SURGICAL TREATMENT FOR CHILDREN WITH CHI.PHASE 3 TRIALS OF DASIGLUCAGON ARE SET TO START IN SECOND HALF OF 2018.CHEK COMBO PUMP SYSTEM FOR STUDY.  Full Article

Zealand Pharma Enters Collaboration Agreement With Roche Diabetes Care
Wednesday, 11 Apr 2018 07:55am EDT 

April 11 (Reuters) - ZEALAND PHARMA A/S ::HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE.ZEALAND RESPONSIBLE FOR CONDUCTING PHASE 3 TRIALS, ROCHE DIABETES CARE PROVIDES ITS ACCU-CHEK COMBO PUMP SYSTEM.  Full Article

Zealand Pharma: Positive Results From First Phase 3 Trial For Treatment Of Severe Hypoglycemia
Tuesday, 20 Mar 2018 08:55am EDT 

March 20 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND PHARMA'S FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA SUCCESSFULLY MEETS ITS PRIMARY OBJECTIVE.‍RESULTS CONFIRM DASIGLUCAGON'S SAFETY PROFILE WITH NO TREATMENT-INDUCED OR TREATMENT-BOOSTED ANTI-DRUG ANTIBODIES​.‍ADDITIONAL RESULTS FROM THIS PHASE 3 TRIAL WILL BE AVAILABLE IN Q2 2018​.‍ADDITIONAL RESULTS FROM TRIAL ARE EXPECTED IN Q2 2018​.‍RESULTS FROM PIVOTAL PHASE 3 EFFICACY TRIAL ARE EXPECTED IN H2 2018.​.  Full Article

Zealand Pharma FY Net Loss At DKK 272.3 Million​
Wednesday, 7 Mar 2018 09:00am EST 

March 7 (Reuters) - ZEALAND PHARMA A/S ::FY 2017 REVENUE DKK ‍​ 139.8 MILLION VERSUS DKK 234.8 MILLION YEAR AGO.‍FY NET LOSS FOR YEAR OF DKK 272.3 MILLION​.NO DIVIDEND HAS BEEN PROPOSED FOR 2017.FOR 2018, ZEALAND EXPECTS A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.‍​.NET OPERATING EXPENSES IN 2018 ARE EXPECTED TO BE WITHIN THE DKK 475-495 MILLION RANGE.‍​.  Full Article

Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates
Tuesday, 20 Feb 2018 03:09am EST 

Feb 20 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES.  Full Article

Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017
Wednesday, 7 Feb 2018 01:33am EST 

Feb 7 (Reuters) - ZEALAND PHARMA A/S ::REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017.ZEALAND REPORTS ROYALTY REVENUE OF DKK 11.3 MILLION/USD 1.8 MILLION FOR Q4 2017.‍IN Q4 SOLIQUA 100/33 SALES GREW 30% OVER PREVIOUS QUARTER​.ROYALTY REVENUE FOR 2017 AMOUNTED TO DKK 38.8 MILLION/USD 6.3 MILLION AN INCREASE OF 59% OVER PREVIOUS YEAR​.  Full Article

Zealand Pharma Makes Initial USD 1.5 Mln Equity Investment In Beta Bionics
Thursday, 21 Dec 2017 09:46am EST 

Dec 21 (Reuters) - ZEALAND PHARMA A/S ::ZEALAND PHARMA MAKES AN INITIAL USD 1.5 MILLION EQUITY INVESTMENT IN SERIES B OFFERING OF BETA BIONICS, INC..POTENTIAL FUTURE INVESTMENTS OF UP TO USD 3.5 MILLION ARE LINKED TO CLINICAL DEVELOPMENT MILESTONES.COLLABORATES WITH BETA BIONICS TO ADVANCE DEVELOPMENT OF ITS DASIGLUCAGON IN ILET(TM).  Full Article

Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon
Thursday, 7 Dec 2017 09:36am EST 

Dec 7 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES.SAYS RESULTS FROM PHASE 3 TRIAL EXPECTED IN H2 2018​.  Full Article

BRIEF-Zealand Pharma Announces Interim Report For The First Quarter Of 2018

* ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST QUARTER OF 2018 Source text for Eikon: Further company coverage: